Karyopharm Therapeutics, Inc. KPTI 深 沪
交易中 05-21 11:31:38 美东时间
7.91
-0.070
-0.88%
华盛通- 最 高8.02
- 今 开7.82
- 成交量 10.98万股
- 最 低 7.75
- 昨 收 7.98
- 总市值 1.79亿
- 52周最高 10.99
- 市盈率 静 --
- 换手率 0.48%
- 52周最低 3.6503
- 委 比 -64.03%
- 总股本 2266.29万
- 历史最高 735.075
- 量 比 0.56
- 振 幅 3.38%
- 历史最低 5.00
- 每 手 1
- 风险率 1.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Karyopharm Therapeutics shares are trading lower. The company reported its Q1 financial results.
Karyopharm Therapeutics shares are trading lower. The company reported its Q1 f...
05-15 23:52
Karyopharm Earnings Call: Trial Wins, Cash Questions
Karyopharm Therapeutics INC (($KPTI)) has held its Q1 earnings call. Read on fo...
05-15 08:20
Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
Karyopharm Therapeutics (NASDAQ:KPTI) released first-quarter financial results ...
05-14 21:37
Karyopharm Q1 FY26 operating loss narrows 20% to $26.76 million; revenue rises 17% to $35.07 million
Karyopharm Q1 FY26 operating loss narrows 20% to $26.76 million; revenue rises 17% to $35.07 million Karyopharm Therapeutics posted Q1 net loss of USD 22.39 million, narrowing 5% from year-ago period, as revenue rose 17% to USD 35.07 million. Operating loss improved 20% to USD 26.76 million, while p
05-14 19:47
Karyopharm Q1 net loss narrows
Karyopharm Q1 net loss narrows Overview U.S. cancer therapy maker's net loss for Q1 narrowed, reflecting improved operating efficiency and disciplined cost management Outlook Karyopharm reaffirms 2026 total revenue guidance of $130 mln to $150 mln Result Drivers GROSS-TO-NET ADJUSTMENTS - Higher net
05-14 19:42
Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $137.489M Est
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $137.489 million estimate.
05-14 19:36
Karyopharm Therapeutics Q1 EPS $(1.24) Beats $(1.40) Estimate, Sales $35.066M Beat $31.399M Estimate
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.40) by 11.43 percent. This is a 55.23 percent increase over losses of $(2.77) per
05-14 19:35
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Raises Price Target to $13
HC Wainwright & Co. analyst Robert Burns maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and raises the price target from $8 to $13.
05-06 20:04
